San Diego-based Ambrx Inc. just raised another $10 Million in new equity funding, according to documents that Ambrx filed with the SEC today. The privately held biotech’s mission is to develop breakthrough therapeutics with genetically-engineered drugs. The company was founded 2003, and as Luke reported last month, previously raised $96 million in venture capital.